Doweck I, Gordon C R, Spitzer O, Melamed Y, Shupak A
Motion Sickness and Human Performance Laboratory, Israeli Naval Hyperbaric Institute, Haifa.
Aviat Space Environ Med. 1994 Jul;65(7):606-9.
In a double-blind, placebo-controlled study, we evaluated the effect of two different doses of cinnarizine in the prevention of seasickness in very rough seas. We divided 95 healthy male subjects into 3 groups which received: cinnarizine 50 mg, cinnarizine 25 mg, and placebo. Seasickness susceptibility and severity were evaluated by a standard questionnaire concerning the subject's condition on previous voyages (seasickness susceptibility), and the subject's condition immediately after a 4-6-h voyage in very rough seas with 3.5 m waves (seasickness severity). Possible side effects of the drug were also evaluated by filling in a further questionnaire. Of the 31 subjects who received cinnarizine 50 mg, 65% felt better during the present voyage than on previous voyages, compared to 41% of the 32 subjects who received cinnarizine 25 mg and 31% of the 32 who received placebo. A significant difference (p < 0.05) was found between the cinnarizine 50 mg and placebo groups, while cinnarizine 25 mg was no more effective than placebo. No notable side effects were found for any drug group. In conclusion, cinnarizine 50 mg was found to be effective in the prevention of seasickness in rough seas.
在一项双盲、安慰剂对照研究中，我们评估了两种不同剂量的桂利嗪在波涛汹涌的海面上预防晕船的效果。我们将95名健康男性受试者分为3组，分别给予：50毫克桂利嗪、25毫克桂利嗪和安慰剂。通过一份关于受试者以往航行时状况的标准问卷（晕船易感性）以及在有3.5米海浪的波涛汹涌的海面上进行4至6小时航行后受试者的即时状况（晕船严重程度）来评估晕船易感性和严重程度。还通过填写另一份问卷来评估药物可能的副作用。在接受50毫克桂利嗪的31名受试者中，65%的人在本次航行中感觉比以往航行时更好，相比之下，接受25毫克桂利嗪的32名受试者中有41%，接受安慰剂的32名受试者中有31%有此感觉。在50毫克桂利嗪组和安慰剂组之间发现了显著差异（p<0.05），而25毫克桂利嗪并不比安慰剂更有效。任何药物组均未发现明显副作用。总之，发现50毫克桂利嗪在预防波涛汹涌的海面上的晕船方面有效。
